Merck & Co., Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Merck & Co., Inc. (MRK) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $40.00 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-28.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2013-02-28
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2012 was $40.00M.
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2011 was -$5.00M, a 101.03% decline from fiscal 2010.
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2010 was $484.00M.
- Merck & Co., Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2009 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2012-12-31 | $40.00M 10-K · filed 2013-02-28 |
| 2011-12-31 | -$5.00M 10-K · filed 2013-02-28 |
| 2010-12-31 | $484.00M 10-K · filed 2013-02-28 |
| 2009-12-31 | $0.00 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |